Aslon, Early Screening for Coronary Artery Disease with AslonHeart-CAD

Non-invasive diagnosis using 12-lead ECG-based AI analysis

Provides comparative information on supportive treatment options to support decision-making

AI medical company Aslon has presented a non-invasive diagnostic assistance solution that screens for coronary artery stenosis at the stable angina stage by analyzing 12-lead electrocardiogram data. The solution is structured to assist medical professionals in making personalized treatment decisions and providing timely treatment for patients by providing information that compares the pros and cons of treatment options, such as drug therapy and stent procedures.

Conventional diagnoses of coronary artery disease are often made after the onset of symptoms such as chest pain, posing a high risk of progression to the advanced stage. Aslon's solution focuses on preventing progression to unstable angina or myocardial infarction by screening for the potential for stenosis during the stable angina stage. The company explains that non-invasive data analysis can be utilized to reduce the burden on patients and systematically manage their progress following treatment.

The main functions can be summarized into four points. First, early identification through electrocardiogram-based AI analysis. Second, supporting the decision-making process between drug therapy and procedures by suggesting treatment directions. Third, standardization and systematization of the clinical process. Fourth, improvement of patients' quality of life and enhancement of the medical system's efficiency through expanded clinical applicability.

Aslon has over eight years of experience in commercializing digital healthcare. Based on its experience in industry-academia-research collaboration and joint commercialization, the company has been enhancing its solutions and plans to continue patient-friendly innovation by integrating AI technology into more medical environments. It also responds to the demand of Gwanak S-Valley through regional cooperation.

The company aims to grow into a global leader in the field of heart health by simultaneously advancing its AI medical software and conducting clinical validation. The plan is to focus on addressing the actual needs of the medical field by enhancing the precision and reliability of early diagnostic assistance.